Neoadjuvant anthracycline-free versus anthracycline-containing chemotherapy combined with dual HER2 blockade in HER2-positive breast cancer: a real-world comparative study


Buyukkuscu A., Isleyen Z. S., Ekinci O. B., Atasever T., Akkaya K., Aydin O., ...Daha Fazla

Breast Cancer Research, cilt.28, sa.1, 2026 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 28 Sayı: 1
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1186/s13058-026-02312-w
  • Dergi Adı: Breast Cancer Research
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals, Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest)
  • Anahtar Kelimeler: HER2-positive breast cancer, Neoadjuvant chemotherapy, TCHP regimen, Pathological complete response, Real-world, Cardiac safety
  • Sağlık Bilimleri Üniversitesi Adresli: Hayır

Özet

Background: Anthracycline-free neoadjuvant chemotherapy combined with dual HER2 blockade represents an alternative to anthracycline-containing regimens in early-stage HER2-positive breast cancer; however, real-world evidence remains limited. Methods: We retrospectively analyzed 162 patients with stage I–III HER2-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab between 2022 and 2025. Patients received anthracycline-free (TCHP/TCH; n = 51) or anthracycline-containing (AC-THP/AC-TH; n = 111) chemotherapy. The primary endpoint was pathological complete response (pCR; ypT0/is ypN0). Secondary endpoints included treatment-related toxicity and cardiac safety. Results: The overall pCR rate was 56.8%. pCR was achieved in 64.7% of patients in the TCHP/TCH group and 53.2% in the AC-THP/AC-TH group (p = 0.168). In multivariable analysis, age > 65 years was associated with a lower probability of pCR (OR 0.08; 95% CI, 0.01–0.57), while hormone receptor–negative status was associated with higher pCR rates (OR 2.21; 95% CI, 1.02–4.76). Grade 3–4 hematologic and gastrointestinal toxicities differed between regimens. Cardiac toxicity was rare and similar between groups. Conclusions: In a real-world setting, anthracycline-free neoadjuvant chemotherapy with dual HER2 blockade achieved pCR rates comparable to anthracycline-containing regimens with acceptable toxicity and preserved cardiac safety, suggesting that it may be a reasonable treatment option for selected patients.